Kennedy’s ‘MAHA transition team’ includes anti-vax activists
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
At least three informal advisers connected to the anti-vaccine movement are assisting Kennedy in filling out his staff as he prepares to lead HHS.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
A Texas case underscores the legal and ethical gray areas physicians have faced since the Supreme Court overturned Roe v. Wade.
District Court Judge Matthew Kacsmaryk could strike down the FDA’s decades-old decision to approve mifepristone.
District Court Judge Matthew Kacsmaryk could strike down the FDA’s decades-old decision to approve mifepristone.
District Court Judge Matthew Kacsmaryk could strike down the FDA’s decades-old decision to approve mifepristone.
The move comes as many GOP-led states are moving to limit access to abortions and transgender care.
The move comes as many GOP-led states are moving to limit access to abortions and transgender care.
There appears to be no clear strategy from either the White House or Capitol Hill to secure the funds.
There appears to be no clear strategy from either the White House or Capitol Hill to secure the funds.
The administration may have enough vaccines and therapeutics to ride out the Omicron surge, but it doesn’t currently have enough money to respond to another variant.
The administration may have enough vaccines and therapeutics to ride out the Omicron surge, but it doesn’t currently have enough money to respond to another variant.
The administration may have enough vaccines and therapeutics to ride out the Omicron surge, but it doesn’t currently have enough money to respond to another variant.